Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression

Key Points

• The research aims to evaluate the efficacy and safety of anti-β-amyloid antibodies in early Alzheimer's disease, including risks related to ARIA.
• Conducted systematic review and meta-analysis of existing studies
• Analyzed data on efficacy, safety, and ARIA risk
• Utilized meta-regression to explore factors influencing outcomes
• Anti-β-amyloid antibodies showed significant efficacy in slowing cognitive decline
• Safety concerns highlighted an increased risk of ARIA events
• Findings underscore the potential benefits and risks associated with treatment